Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Roche’s giredestrant secures FDA priority review for breast cancer

Summary by Verdict Hospital
The US FDA has accepted priority review of the NDA for Roche’s investigational oral SERD, giredestrant, for breast cancer.The post Roche’s giredestrant secures FDA priority review for breast cancer appeared first on Hospital Management.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

4 Articles

cancernetwork.comcancernetwork.com

FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer

Giredestrant improved invasive disease-free survival vs endocrine therapy for patients with ER+, HER2– early breast cancer in the phase 3 lidERA trial.

Read Full Article
pharmaceutical-technology.compharmaceutical-technology.com
+2 Reposted by 2 other sources

Roche’s giredestrant secures FDA priority review for breast cancer

The US FDA has accepted priority review of the NDA for Roche’s investigational oral SERD, giredestrant, for breast cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

pharmaceutical-technology.com broke the news on Wednesday, June 3, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Breast Cancer icon

Breast Cancer

FDA icon

FDA

United States icon

United States

Health & Medicine icon

Health & Medicine

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal